<unk>  is an antineoplastic agent that is FDA approved for the treatment of metastatic colorectal cancer (mcrc)，non-squamous non–small cell lung cancer (nsclc),glioblastoma, metastatic renal cell carcinoma (mrcc). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hypertension, any grade, alopecia, hand-foot syndrome due to cytotoxic therapy
abdominal pain, any grade, constipation, any grade, diarrhea, loss of appetite, stomatitis, taste sense altered, 
hemorrhage, any grade, asthenia, dizziness, headache, any grade
proteinuria, any grade, dyspnea, epistaxis, upper respiratory infection.
Bevacizumab
Necitumumab
Bortezomib
Panitumumab
Sunitinib
Ranibizumab
Ruxolitinib
Ceritinib